Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India.
Pharm Biol. 2011 Nov;49(11):1137-43. doi: 10.3109/13880209.2011.572077.
The pathogenesis of diabetic cardiomyopathy (DCM) is complex, and the therapeutic options available to treat DCM are limited. The present study was designed to investigate the effect of Aegle marmelos (L.) Correa (Rutaceae) leaf extract on early stage DCM in alloxan-induced diabetic rats.
Diabetes was induced in Wistar rats (150-200 g) by injecting alloxan (150 mg kg(-1); i.p.). Ethanol extract of A. marmelos leaves was administered at varying doses (100, 200, and 400 mg kg(-1)) and tolbutamide (100 mg kg(-1)) as standard. Fasting blood glucose (FBG), total cholesterol, thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), lactate dehydrogenase (LDH) and creatine kinase (CK) were determined by standard methods.
A. marmelos extract (AME) was found to decrease the levels of FBG, total cholesterol, TBARS, LDH and CK, and increase the levels of GSH, CAT and SOD dose dependently as compared to diabetic control groups. The maximum dose-dependent decrease in TBARS (63.46%), LDH (34.04%), CK (53.14%), and increase in GSH (64.91%), CAT (59.34%), SOD (69.65%) was evident at an optimum dose of 200 mg kg(-1). Histopathological studies revealed salvage in the morphological derangements as indicated by absence of necrosis and marked decrease in inflammatory cells in AME-treated groups as compared to diabetic control.
The present investigations conclude that treatment with AME attenuates the severity and improves the myocardium in the early stages of alloxan-induced DCM at a dose of 200 mg kg(-1).
糖尿病心肌病（DCM）的发病机制复杂，可用于治疗 DCM 的治疗选择有限。本研究旨在探讨酸模叶蓼（Rutaceae）叶提取物对链脲佐菌素诱导的糖尿病大鼠早期 DCM 的影响。
通过向 Wistar 大鼠（150-200g）注射链脲佐菌素（150mg/kg，ip）诱导糖尿病。给予酸模叶蓼叶的乙醇提取物以不同剂量（100、200 和 400mg/kg）和甲苯磺丁脲（100mg/kg）作为标准。通过标准方法测定空腹血糖（FBG）、总胆固醇、硫代巴比妥酸反应物质（TBARS）、还原型谷胱甘肽（GSH）、过氧化氢酶（CAT）、超氧化物歧化酶（SOD）、乳酸脱氢酶（LDH）和肌酸激酶（CK）。
与糖尿病对照组相比，酸模叶蓼提取物（AME）被发现可降低 FBG、总胆固醇、TBARS、LDH 和 CK 的水平，并且可剂量依赖性地增加 GSH、CAT 和 SOD 的水平。在 200mg/kg 的最佳剂量下，TBARS（63.46%）、LDH（34.04%）、CK（53.14%）的最大剂量依赖性降低和 GSH（64.91%）、CAT（59.34%）、SOD（69.65%）的最大增加最为明显。与糖尿病对照组相比，AME 治疗组的形态学紊乱得到挽救，表明不存在坏死和炎症细胞明显减少。
目前的研究表明，AME 治疗可减轻 200mg/kg 剂量的链脲佐菌素诱导的 DCM 早期阶段的严重程度并改善心肌。
